NASDAQ:MRTX - Nasdaq - US60468T1051 - Common Stock - Currency: USD
Overall MRTX gets a fundamental rating of 4 out of 10. We evaluated MRTX against 563 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRTX as it has an excellent financial health rating, but there are worries on the profitability. MRTX is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -64.25% | ||
ROE | -76.69% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 88.5% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 8.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 7.54 | ||
Quick Ratio | 7.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
58.7
-0.1 (-0.17%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 107.82 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.35 | ||
P/tB | 4.42 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -64.25% | ||
ROE | -76.69% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 88.5% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 43.91% | ||
Cap/Sales | 4.82% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 7.54 | ||
Quick Ratio | 7.39 | ||
Altman-Z | 8.55 |